Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 25, 2013Boston Scientific comunica i risultati positivi a sei mesi dello studio clinico sulla valvola Lotus™I dati di REPRISE II premiati con il Miglior Abstract 2013 al PCR London Valves Course
La Boston Scientific Corporation (NYSE: BSX) ha comunicato i risultati positivi a sei mesi dei primi 60 pazienti arruolati nello studio clinico REPRISE II che valutava la sicurezza e la...
-
Sep 17, 2013
REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course Boston Scientific Corporation (NYSE: BSX) reported favorable six-month results from the first 60 patients enrolled in the...
-
Sep 12, 2013
In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System, Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the EVOLVE II...
-
Sep 11, 2013A diferencia del tratamiento farmacológico por sí solo, la termoplastia aporta efectos beneficiosos que duran años en lugar de horas
Una novedosa tecnología de Boston Scientific para el tratamiento del asma grave ha demostrado su seguridad y eficacia a lo largo de cinco años, según los da The Journal of Allergy and Clinical...
-
Sep 10, 2013
Langzeitdaten in The Journal of Allergy and Clinical Immunology veröffentlicht: Patienten mit schwerem Asthma profitieren für Jahre von einer nicht-medikamentösen Therapie, wo Medikamente...
-
Sep 9, 2013I benefici comportati dalla termoplastica bronchiale perdurano per anni, anziché per ore, diversamente da quanto accade col solo trattamento farmacologico.
News Newsroom Italia Asma grave Archivio Comunicati Stampa 2013 Sep 09, 2013 Comunicato Stampa The Journal of Allergy and Clinical Immunology pubblica i dati sulla termoplastica bronchiale che...
-
Sep 4, 2013Unlike Medications Alone, Bronchial Thermoplasty Provides Benefits That Last for Years Rather Than Hours
A breakthrough Boston Scientific technology for the treatment of severe asthma has been shown to be safe and effective over at least five years, according to data published online in a key medical...
-
Jul 19, 2013
First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System Boston Scientific Corporation (NYSE: BSX) has launched a...
-
Jul 19, 2013
First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System Boston Scientific Corporation (NYSE: BSX) has launched a...
-
Jul 19, 2013Boston Scientific Launches Trial To Evaluate Neurostimulation For Treatment Of Chronic Migraine [EN]First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System
Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision™ System can safely and effectively treat...